SuperworthFossil free cash flow FOSL
Cash from operations less capital spending, by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jul 4, 2026
- −$41.2M
- Latest quarter, Q2 FY26
- −$10.1M
- −217% on a year earlier
- Fiscal year 2025
- −$60.5M
- −251% on the year before
Fossil's free cash flow was −$41.2M over the twelve months to Jul 4, 2026.
In its latest quarter, Q2 FY26, it was −$10.1M, down 217% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | −$60.5M | −251% |
| FY2024 | $39.9M | n/a |
| FY2023 | −$68M | n/a |
| FY2022 | −$124.1M | −412% |
| FY2021 | $39.7M | −57% |
| FY2020 | $92.5M | n/a |
| FY2019 | −$35.1M | −115% |
| FY2018 | $230.2M | +49% |
| FY2017 | $154M | +7% |
| FY2016 | $144.5M | −49% |
| FY2015 | $281M | −4% |
| FY2014 | $293.1M | −7% |
| FY2013 | $316.4M | −7% |
| FY2012 | $339.2M | +140% |
| FY2011 | $141.4M | −13% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$10.1M | −217% | −$41.2M | |
| Q1 FY26 | −$22.7M | n/a | −$22.5M | |
| Q4 FY25 | $14.1M | −51% | −$60.5M | |
| Q3 FY25 | −$22.5M | n/a | −$46M | |
| Q2 FY25 | $8.6M | −76% | −$47.6M | |
| Q1 FY25 | −$60.6M | n/a | −$19.7M | |
| Q4 FY24 | $28.5M | −40% | $39.9M | |
| Q3 FY24 | −$24.1M | n/a | $58.6M | |
| Q2 FY24 | $36.6M | +4182% | $55.2M | |
| Q1 FY24 | −$1.1M | n/a | $19.4M | |
| Q4 FY23 | $47.1M | −53% | −$68M | |
| Q3 FY23 | −$27.5M | n/a | −$15.8M |
Against its peers
Companies in Medical - Instruments & Supplies nearest Fossil's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| FOSLFossil | −10.6% |
| EMBCEmbecta | n/m |
| TCMDTactile Systems Technology | 5.0% |
| INFUInfuSystem | 8.3% |
| MDXGMimedx | n/m |
| UTMDUtah Medical Products | 4.8% |
| MOVMovado | 10.2% |
| PDEXPro DEX | 3.4% |
| IRMDIradimed | 2.3% |
| STAAStaar Surgical | −0.6% |
| BVSBioventus | 7.5% |
| Peer median | 4.9% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Fossil
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.